|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
On Monday of this year’s American Society of Hematology (ASH) meeting, researchers presented new results indicating that the novel treatment with Velcade (bortezomib), Doxil (doxorubicin), and dexamethasone (VDD) in newly-diagnosed myeloma patients is superior to a competing novel treatment with thalidomide (Thalomid) and dexamethasone (TD) both before and after autologous stem cell transplantation (ASCT).
From July 2003 to May 2005, 31 patients with newly-diagnosed myeloma were treated with three 5-week cycles of TD regimen at the University of Michigan Cancer …
At this year's American Society of Hematology (ASH) meeting, scientists presented on Sunday new results that indicate a promising four-drug regimen in patients with newly-diagnosed multiple myeloma. The four-drug cocktail consisted of Velcade (bortezomib), cyclophosphamide, dexamethasone, and thalidomide (Thalomid). Following six cycles of treatment, the patients proceeded to stem cell harvest, transplant, and/or maintenance therapy.
The response rate was tested by determining the decrease of monoclonal protein in the patients’ serum and/or urine. Scientists defined a response to the treatment …
At this year's American Society of Hematology (ASH) meeting, the International Myeloma Foundation (IMF) will report new progress on multiple myeloma research and will introduce five long-term patients who have benefited from novel treatments. Although multiple myeloma is an incurable cancer, new treatments used in combination and in sequence have dramatically improved the quality of life for many patients.
The five patients represented by the IMF at the meeting will be: Hardy Jones, a five-year multiple myeloma survivor who now …
On November 18, the International Myeloma Foundation (IMF) announced a global research partnership that will study cancers affecting the immune system, including multiple myeloma. The collaboration is between IMF Chairman Brian G.M. Durie, M.D., of the United States; Luc Montagnier, M.D., co-recipient of the 2008 Nobel Prize in medicine, of France; and Howard Urnovitz, Ph.D., CEO of Chronix Biomedical, of Germany.
Dr. Montagnier’s pioneering research, which discovered the virus that causes AIDS, will …
Swedish scientists have identified agricultural and baking occupations, among others, as having excess risk for multiple myeloma, which they attributed to high exposure of chemicals and sensitizing agents. Although several risk factors (including male gender, age, and African-American ethnicity) had been previously established, no environmental risk factors had been identified.
Nearly three million Swedish workers were categorized by occupation and age, and their health records were tracked between 1971 and 1989. Scientists tracked these records through the …
The Multiple Myeloma Research Foundation (MMRF) held its 12th Annual “Friends for Life” Fall Gala on Saturday, November 1, in Greenwich, Connecticut. Attended by more than nine hundred guests, the event raised over $1.5 million for the organization. The MMRF, the leading global fundraiser for multiple myeloma research, directs its donations toward development of novel treatments of the disease.
Deborah Norville, host of Inside Edition and author of Thank You Power, …
Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [...]
